Coffee May Lower Risk of Melanoma

By Sondra Forsyth

Java lovers rejoice! According to a study published January 20^th 2015 in the Journal of the National Cancer Institute, drinking four or more cups of coffee a day may lower the risk of malignant melanoma. Previous studies have suggested that coffee consumption has a protective effect against non-melanoma skin cancers, but the protective effect for cutaneous malignant melanoma has been less clear until now.

A release from the publisher reports that in order to determine if there is an association between coffee consumption and risk of cutaneous melanoma, Erikka Loftfield, M.P.H., of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, and colleagues used data from the NIH-AARP Diet and Health Study. Information on coffee consumption was obtained from 447,357 non-Hispanic white subjects with a self-administered food-frequency questionnaire in 1995/1996, with a median follow-up of 10 years. All subjects included in the analysis were cancer-free at baseline, and the authors adjusted for ambient residential ultraviolet radiation exposure, body mass index, age, sex, physical activity, alcohol intake, and smoking history.

Overall, the highest coffee intake was inversely associated with a risk of malignant melanoma, with a 20% lower risk for those who consumed four cups per day or more. There was also a trend toward more protection with higher intake, with the protective effect increasing from one or fewer cups to four or more. The effect was statistically significant for caffeinated but not decaffeinated coffee and only for protection against malignant melanoma but not melanoma in-situ, which may have a different etiology.

The researchers point out that the results are preliminary and may not be applicable to other populations, and therefore additional investigations of coffee intake are needed. However, they conclude that “Because of its high disease burden, lifestyle modifications with even modest protective effects may have a meaningful impact on melanoma morbidity.”